Home › Research › Biomarkers
ADAM10: Biomarker of mild cognitive impairment but not of cognitive frailty
Izabela Pereira Vatanabe, Renata Valle Pedroso, Patricia Regina Manzine, Marcos Hortes Nisihara Chagas, Daiene de Morais Fabrício, Marina Mantellatto Grigoli, Marina Araújo Naves, Henrique Pott-Jr et al.. Experimental gerontology, 2021-03-03
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Mild cognitive impairment (MCI) associated with physical frailty gave rise to the new concept of cognitive frailty. Previous studies have suggested that MCI may represent a condition that precedes Alzheimer's disease (AD), in view of its higher conversion rate to dementia, when compared with the conversion rate of cognitively healthy older adults. Therefore, and considering that MCI represents a reversible condition, the identification of biomarkers for this condition is imperative to early diagnosis. Accordingly, this study aimed to assess whether the platelet and plasma levels of ADAM10 could be related with the concomitant conditions of MCI and physical frailty, in order to support a new blood-based biomarker for the construct of cognitive frailty. Sixty-one adults aged 60 years or older participated in this study. The results showed that ADAM10 levels are reduced in platelets (p < 0.05) and increased in plasma (p < 0.05) of older adults with MCI compared to healthy controls, regardless of the physical frailty condition. The analysis of the ROC curve of ADAM10 in platelets showed sensitivity and specificity of 72.7 and 73.9%, respectively, to correct differentiate between participants with preserved cognition from those with MCI. For plasma samples, ADAM10 presented 62.5 and 90.0%, sensitivity and specificity respectively, to differentiate the aforementioned conditions. Together with other clinical criteria blood ADAM10 could be a relevant, low-invasive, low-cost and fast processing biomarker tool to help in the early and accurate diagnosis of MCI, however this marker was not able to identify cognitive frailty.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vatanabe, I. P., Pedroso, R. V., Manzine, P. R., Chagas, M. H. N., Fabrício, D. d. M., Grigoli, M. M., et al. (2021). ADAM10: Biomarker of mild cognitive impairment but not of cognitive frailty. Experimental gerontology. https://doi.org/10.1016/j.exger.2021.111303
Vancouver
Vatanabe IP, Pedroso RV, Manzine PR, Chagas MHN, Fabrício DdM, Grigoli MM, et al. ADAM10: Biomarker of mild cognitive impairment but not of cognitive frailty. Experimental gerontology. 2021. doi:10.1016/j.exger.2021.111303. PMID: 33675901.
BibTeX
@article{vatanabe2021-33675901,
author = {Vatanabe, Izabela Pereira and Pedroso, Renata Valle and Manzine, Patricia Regina and Chagas, Marcos Hortes Nisihara and Fabrício, Daiene de Morais and Grigoli, Marina Mantellatto and Naves, Marina Araújo and Pott-Jr, Henrique and others},
title = {{ADAM10: Biomarker of mild cognitive impairment but not of cognitive frailty}},
journal = {Experimental gerontology},
year = {2021},
doi = {10.1016/j.exger.2021.111303},
pmid = {33675901},
url = {https://doi.org/10.1016/j.exger.2021.111303}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Mild cognitive impairment (MCI) associated with physical frailty gave rise to the new concept of cognitive frailty.
- Previous studies have suggested that MCI may represent a condition that precedes Alzheimer's disease (AD), in view of its higher conversion rate to dementia, when compared with the conversion rate of cognitively healthy older adults.
- The results showed that ADAM10 levels are reduced in platelets (p < 0.05) and increased in plasma (p < 0.05) of older adults with MCI compared to healthy controls, regardless of the physical frailty condition.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect size73.9%; 90.0%
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 25 of the 56 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Experimental gerontology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33675901) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 25 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 25 of the 56 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.